Canaccord Adams maintains a 'Buy' rating on Onyx Pharmaceuticals (Nasdaq: ONXX), lowers price target to $37.

Canaccord analysts says, "Onyx ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE